AR017686A1 - Una proteina mutante hedgehog activa, un proceso para su preparacion y su uso para propositos farmaceuticos - Google Patents

Una proteina mutante hedgehog activa, un proceso para su preparacion y su uso para propositos farmaceuticos

Info

Publication number
AR017686A1
AR017686A1 ARP980106010A ARP980106010A AR017686A1 AR 017686 A1 AR017686 A1 AR 017686A1 AR P980106010 A ARP980106010 A AR P980106010A AR P980106010 A ARP980106010 A AR P980106010A AR 017686 A1 AR017686 A1 AR 017686A1
Authority
AR
Argentina
Prior art keywords
activity
preparation
mutant protein
pharmaceutical purposes
active mutant
Prior art date
Application number
ARP980106010A
Other languages
English (en)
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of AR017686A1 publication Critical patent/AR017686A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un mutante de la proteína hedgehog procesada post-translacionalmente, la cual, tiene un peso molecular de 22 +- 2 kDa en condiciones de alquilacion;tiene un peso molecular de 24 +- 2 kDa en condiciones de reduccion; se estabiliza con respecto a su actividad, mediante la suramina; se inactiva cuando 8 o másaminoácidos se escinden por el extremo N; se inactiva en un 90% o más cuando se incuba con 10 mmoles/litro de DTE durante 2,5 horas a 37*C; induce unaactividad para la fosfatasa alcalina de aprox. 90 nmoles de pNP/min/mg a una concentracion de 5nmoles/litro en presencia de suramina; no se modifica medianteel colesterol; y tiene una actividad que es por lo menos 50 veces la de la proteína hh recombinante aislada del citoplasma de E. coli, posee una actividadaumentada varias veces.
ARP980106010A 1997-11-28 1998-11-26 Una proteina mutante hedgehog activa, un proceso para su preparacion y su uso para propositos farmaceuticos AR017686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97120891A EP0919618A1 (de) 1997-11-28 1997-11-28 Aktive Hedgehog-Protein-Mutante, Verfahren zur Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
AR017686A1 true AR017686A1 (es) 2001-09-12

Family

ID=8227694

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106010A AR017686A1 (es) 1997-11-28 1998-11-26 Una proteina mutante hedgehog activa, un proceso para su preparacion y su uso para propositos farmaceuticos

Country Status (5)

Country Link
EP (1) EP0919618A1 (es)
AR (1) AR017686A1 (es)
CO (1) CO4850631A1 (es)
PE (1) PE20000004A1 (es)
ZA (1) ZA9810846B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides

Also Published As

Publication number Publication date
CO4850631A1 (es) 1999-10-26
ZA9810846B (en) 1999-06-01
PE20000004A1 (es) 2000-01-29
EP0919618A1 (de) 1999-06-02

Similar Documents

Publication Publication Date Title
ATE273320T1 (de) Fusogene liposomen
EA199900979A1 (ru) Композиции активированного протеина
NL300281I2 (nl) Exenatide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
EA200300856A1 (ru) Долгоживущие производные рилизинг-фактора гормона роста
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
IT1262896B (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
NO20063026L (no) Antistoffer
ATE453665T1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
CO5640149A2 (es) Formulaciones parenterales de un peptido para el tratamiento de lupus sistematico eritematoso
BR9705527A (pt) Sistemas de expressão auto-melhorador, farmacologicamente controláveis.
BR9810002A (pt) Preparação de <244>1-at nativa purificada cromatograficamente, processo para a preparação da mesma, e, utilização de um material de suporte
DE60024100D1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
ES2190471T3 (es) Procedimiento para producir derivados de guanidina, intermedios de dichos compuestos y su produccion.
AR017686A1 (es) Una proteina mutante hedgehog activa, un proceso para su preparacion y su uso para propositos farmaceuticos
DE69831979D1 (de) Gefrorenes lebensmittel
ATE481420T1 (de) Il-21-derivate
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
AU2002326070A1 (en) Peyers's patch and/or m-celle targeting ligands
ATE315577T1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
ECSP982758A (es) Un mutante activo de proteina hedgehog, un proceso para su preparacion y su uso para fines farmaceuticos
NO983437D0 (no) Administreringsformer med umiddelbar frigivelse, samt fremgangsmÕte for fremstilling av slike
CO5060478A1 (es) Secuencia del gen relacionado con agiopoyetina scarface 3
ES2156812B1 (es) Una proteasa extracelular de acremonium chrysogenum con actividad cpc-acetilhidrolasa y su utilizacion para la sintesis de derivados desacetilados de cefalosporina c e inactivacion del gen para aumentar la produccion de cefalosporina.
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
ES2170161T3 (es) Nuevos conjugados de principios activos y proteinas.